Las Vegas Mobile IV Therapy
- Stem Cell Therapy
- NAD IV Therapy
- Vitamin IV Therapy
- IV Therapy
- IV Hydration
Las Vegas, NV
Las Vegas supports a regenerative medicine market shaped by both private clinics and regional academic medicine. Local referral networks run through University Medical Center, Sunrise Hospital, and Cleveland Clinic Lou Ruvo, and stem cell practice in the area spans Summerlin, Henderson, and the Strip medical offices. Patient demand splits across three buckets: orthopedic injections for active adults and aging athletes, neurological and autoimmune protocols marketed to longevity-focused patients, and IV-based allogeneic products offered by private wellness clinics. The FDA classifies most stem cell injections for orthopedic, neurological, or longevity use as investigational biologics under 21 CFR Part 1271, meaning they require either a Biologics License or an active Investigational New Drug authorization. Autologous bone marrow and adipose products may qualify as Section 361 when minimally manipulated and used for homologous function. Nevada Assembly Bill 209 (2021) added state-level regulation of stem cell advertising and patient disclosure. The Nevada Board of Medical Examiners oversees physician practice, and Las Vegas-area clinics fall under active FDA and state scrutiny given the volume of stem cell advertising. The 14 Las Vegas clinics listed below have been reviewed against our vetting criteria, including federal NPI lookup, OIG exclusion screening, and Nevada Board of Medical Examiners licensure checks.
Regulatory context
Nevada cellular therapy is governed by 21 CFR Part 1271. Section 361 covers minimally manipulated HCT/Ps used for homologous use without premarket approval. Section 351 covers products that are more than minimally manipulated, used non-homologously, or combined with another article, and these require an IND for clinical use or a BLA for marketing. Most stem cell, stromal vascular fraction, and exosome therapies marketed in Nevada for orthopedic, neurologic, and longevity indications are Section 351 biologics that lack FDA approval. Las Vegas is a high-volume regenerative medicine market with substantial federal scrutiny.
The FDA has issued warning letters to Nevada clinics offering stem cell and exosome therapies, with concentration in Las Vegas. The Nevada State Boards of Medical Examiners and Osteopathic Medicine have disciplined physicians for unprofessional conduct including misleading regenerative medicine advertising. The Nevada Attorney General has used the Deceptive Trade Practices Act to pursue providers making unsupported clinical claims. The state's medical tourism profile and density of regenerative clinics keep it on FDA's enforcement radar.